Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (173)	4/19/2002 6:05:04 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 598

The cc has many new details about the development program for T67. After listening it's also pretty easy to imagine what its asco data looks like. If the stock response has been due to not going forward in glioma, breast and cc, then the market does not seem to appreciate what is the purpose of P1. One question from the queue: Why do you file abstracts on negative data? That they are moving up the HCC dose 50% and potentially cutting the infusion time in 1/2, in light of efficacy in all surrogate measures in P2...well that sounds pretty good considering what the market might look like for a novel HCC treatment. Can't imagine what the T67/dox trial might result in, but that's why they do it. BTW, expect FDA meeting 3Q, but papers aren't even filed yet, so..... Wilder